Pivotal Legal Case Settlement Includes Ekso Bionics Ekso GT(TM) Robotic Exoskeleton
(Thomson Reuters ONE) -
Paralyzed Gunshot Victim is First Recipient of a Fully Remunerated Ekso GT Suit
for Home Rehabilitation in the UK
CANARY WHARF, LONDON, March 31, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings,
Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced that Dale Messenger,
who was left paralyzed with an L1 incomplete spinal cord injury after suffering
a gunshot wound, settled a long running case at the High Court in the United
Kingdom. His damages settlement includes, among other items, the purchase cost
of an Ekso Bionics Ekso GT robotic exoskeleton, its replacement over the years,
and related utilization costs.
"During my case, many subjects were discussed and items of equipment reviewed
including other, similar exoskeletons. One such item was the Ekso and it proved
to be more valuable than I could imagine, and in a league of its own," said
Dale. "The benefit I experience from the Ekso ranges from pain relief,
improvements to my bladder/bowel function and more recently an increase in my
motor function and sensation."
Ben Rogers, Partner at Stewarts Law LLP, the UK's largest litigation only law
firm that specializes in high value and complex disputes added: "So far as we
are aware, this is the first time that damages have been recovered in England &
Wales to reimburse for the cost of a home rehabilitation device and a trained
physiotherapist to operate it. The settlement reflects both the ability in
principle to recover damages for the Ekso Bionics robotic exoskeleton and of
course the need for specialized medical and legal experts to assist with
processing these claims."
Nathan Harding, Ekso Bionics chief executive officer adds, "This is a major step
for individuals who are looking to improve their rehabilitation options from
their home. We believe the data our partners are collecting at Europe's top
rehabilitation centers will begin to show that the Ekso Bionics Ekso GT(TM)
robotic exoskeleton may be effective in many of the ways Dale has experienced,
including aiding recovery and potentially reducing secondary complications. Now
that we are seeing patients get access to our technology thru legal settlements
for home rehabilitation, we are eager to see how this improved access might
impact overall patient outcomes."
Ekso Bionics' lead product, the Ekso GT(TM) robotic exoskeleton, is a wearable
bionics suit that enables individuals with any amount of lower extremity
weakness to stand up and walk over ground. Ekso Bionics is forging a new
frontier in rehabilitation for people living with the consequences of stroke,
spinal cord injury, and other neurological conditions affecting gait.
About Ekso Bionics (OTCQB:EKSO)
Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the
field of robotic exoskeletons, or wearable robots, to augment human strength,
endurance and mobility. The company's first commercially available medical
product called Ekso has helped thousands of people living with gait impairment
or paralysis take millions of steps not otherwise possible. By designing and
creating some of the most forward-thinking and innovative solutions for people
looking to augment human capabilities, Ekso Bionics is helping people rethink
current physical limitations and achieve the remarkable.
Facebook: www.facebook.com/eksobionics
Twitter: (at)eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
About Stewarts Law
The UK's largest litigation-only law firm specializes in high-value and complex
disputes. Stewarts Law's lawyers are renowned for offering corporate clients and
individuals innovative, ground-breaking solutions. Its specialist departments
include aviation and travel, clinical negligence, commercial litigation,
competition litigation, divorce and family, employment, international
arbitration, investor protection litigation, personal injury and tax litigation.
Each department has an international reputation for excellence. With
international strategic partnerships in place with law firms around the world,
Stewarts Law enables clients to take a global approach to litigation. Its
Personal Injury department is consistently top-ranked by Chambers and Legal
500, the leading directories in the legal industry.
Stewarts Law contact
Katy McEwen
Marketing Executive
Email: kmcewen(at)stewartslaw.com
Phone: (0)20 7822 8037
www.stewartslaw.com
Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 415.302.4777
hdarling(at)eksobionics.com
Investor Contact:
John Graziano, The Trout Group
Phone: 646.378.2942
jgraziano(at)troutgroup.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements may
include, without limitation, statements regarding (i) the plans and objectives
of management for future operations, including plans or objectives relating to
the design, development and commercialization of human exoskeletons, (ii) a
projection of financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's future financial
performance and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations, estimates and
assumptions and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual results and
the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company's
inability to obtain adequate financing to fund the Company's operations and
necessary to develop or enhance our technology, the significant length of time
and resources associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the Company's products,
the failure of our sales and marketing organization or partners to market our
products effectively, adverse results in future clinical studies of the
Company's medical device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or maintain
regulatory approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, and the Company's failure to
implement the Company's business plans or strategies. These and other factors
are identified and described in more detail in the Company's filings with the
SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com.
The Company does not undertake to update these forward-looking statements.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ekso Bionics via GlobeNewswire
[HUG#1907737]
Unternehmensinformation / Kurzprofil:
Datum: 31.03.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 382250
Anzahl Zeichen: 8589
contact information:
Town:
Richmond
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 118 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pivotal Legal Case Settlement Includes Ekso Bionics Ekso GT(TM) Robotic Exoskeleton"
steht unter der journalistisch-redaktionellen Verantwortung von
Ekso Bionics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
